Safety & side effects
In the one controlled trial that reported safety, treatment-emergent adverse events were common in both arms, 87.5% on…
What we know about safety, and the large gaps
In the one controlled trial that reported safety, treatment-emergent adverse events were common in both arms, 87.5% on ipamorelin and 94.8% on placebo, so tolerability was similar between them. That is reassuring as far as it goes, and it does not go far: every published human exposure was single-dose or ran at most from postoperative day 1 to 7, and that same trial recorded serious events, including two deaths, in the ipamorelin arm.
This unit separates the reassuring short-term data from the real, mostly theoretical, longer-term concerns: blood sugar, IGF-1 and cancer-risk questions, the acromegaly-spectrum risks of chronic stimulation, who should avoid it, and what monitoring a cautious clinician would want. As always, this is education, not medical advice.